Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer

Next Previous
Trial Profile

Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms EXPERT

Most Recent Events

  • 19 Jan 2019 Results (n=77) presented at the 2019 Gastrointestinal Cancers Symposium
  • 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
  • 23 May 2016 Results of a pooled analysis from EXPERT and EXPERT-C trials (n=269) published in the Annals of Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top